Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the first-line treatment, with methotrexate commonly used when steroidsparing therapy is needed. For refractory or multisystem disease, laterline options such as infliximab, adalimumab, and acthar gel offer additional support. Despite these established approaches, gaps remain in managing chronic immunosuppression and recurring disease. Emerging agents, including efzofitimod (aTyr Pharma) and XTMAB16 (Xentria), may help broaden options for difficult-to-treat patients. This report provides insight into real-world prescribing patterns to help developers better understand current practices and identify opportunities for emerging therapies.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed sarcoidosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed sarcoidosis patients?
- How have biological therapies been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of sarcoidosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of sarcoidosis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key drugs: Acthar gel, adalimumab, infliximab, methotrexate, prednisone
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
